Viewing Study NCT02568267


Ignite Creation Date: 2025-12-25 @ 12:41 AM
Ignite Modification Date: 2026-02-25 @ 5:25 PM
Study NCT ID: NCT02568267
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-04
First Post: 2015-10-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Sponsor: Hoffmann-La Roche
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Cholangiocarcinoma View
None Colorectal Cancer View
None Head and Neck Neoplasms View
None Lymphoma, Large-Cell, Anaplastic View
None Melanoma View
None Neuroendocrine Tumors View
None Non-Small Cell Lung Cancer View
None Ovarian Cancer View
None Pancreatic Cancer View
None Papillary Thyroid Cancer View
None Primary Brain Tumors View
None Renal Cell Carcinoma View
None Sarcomas View
None Salivary Gland Cancers View
None Adult Solid Tumor View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Entrectinib View
None RXDX-101 View
None TrkA View
None TrkB View
None TrkC View
None NTRK1 View
None NTRK2 View
None NTRK3 View
None ROS1 View
None ALK View
None Trk Fusions View
None NTRK Gene Rearrangements View
None ROS1 Fusions View
None ROS1 Gene Rearrangements View
None ALK Fusions View
None ALK Gene Rearrangements View
None Basket study View
None Non-small cell lung cancer View
None Colorectal cancer View
None Salivary gland cancers View
None Primary brain tumors View
None Melanoma View
None Sarcomas View
None Papillary thyroid cancer View
None Renal cell cancer View
None Pancreatic cancer View
None Breast cancer View
None Cholangiocarcinoma View
None Head & Neck cancers View
None Ovarian cancer View
None Neuroendocrine tumors View